FDA Grants Fast Track Status to Breast Cancer Therapy Candidate Balixafortide Combined with Halaven
News
The U.S. Food and Drug Administration granted fast track status to Polyphor’s immuno-oncology candidate balixafortide (POL6326) in combination with Halaven (eribulin mesylate) to treat a subset of patients with metastatic ... Read more